“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: BRCA2 gene mutation and risk of aggressive prostate cancer

€3.03

SKU: product-article-11102 Category: General

Description
Reviews (0)

Description

BRCA2 gene mutation and risk of aggressive prostate cancer

Reviews

There are no reviews yet.

Be the first to review “Article: BRCA2 gene mutation and risk of aggressive prostate cancer”

You must be logged in to post a review.

Top

Article: BRCA2 gene mutation and risk of aggressive prostate cancer

Description

Reviews

Related products

Article: Highlights in breast cancer

1 year subscription print edition of the Belgian Journal of Hematology (BJH)

Article: Highlights in digestive oncology

Article: Highlights in breast cancer